(Sharecast News) - Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic cough drug after unsuccessful results late-stage clinical trial.
Refractory chronic cough or RCC is a persistent cough lasting more than eight weeks, and is known as an...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE